biostudies-literatureWaldman SANCI NIH HHS745-52https://www.ebi.ac.uk/biostudies/studies/S-EPMC2756012biostudies-literatureUnknown301(7)<h4>Context</h4>The established relationship between lymph node metastasis and prognosis in colorectal cancer suggests that recurrence in 25% of patients with lymph nodes free of tumor cells by histopathology (pN0) reflects the presence of occult metastases. Guanylyl cyclase 2C (GUCY2C) is a marker expressed by colorectal tumors that could reveal occult metastases in lymph nodes and better estimate recurrence risk.<h4>Objective</h4>To examine the association of occult lymph node metastases detected by quantifying GUCY2C messenger RNA, using the reverse transcriptase-polymerase chain reaction, with recurrence and survival in patients with colorectal cancer.<h4>Design, setting, and participants</h4>Prospective study of 257 patients with pN0 colorectal cancer enrolled between March 2002 and JJAMAAssociation of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer.PMC2756012CA95026R01 CA095026-01A2R21 CA112147CA75123CA112147R01 CA075123-02R01 CA095026R21 CA112147-01R01 CA075123R33 CA112147Li YWeinberg DSBonaccorso CHyslop TSchulz SHaaf JWaldman SABarkun ANielsen KfalseAssociation of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer.<h4>Context</h4>The established relationship between lymph node metastasis and prognosis in colorectal cancer suggests that recurrence in 25% of patients with lymph nodes free of tumor cells by histopathology (pN0) reflects the presence of occult metastases. Guanylyl cyclase 2C (GUCY2C) is a marker expressed by colorectal tumors that could reveal occult metastases in lymph nodes and better estimate recurrence risk.<h4>Objective</h4>To examine the association of occult lymph node metastases detected by quantifying GUCY2C messenger RNA, using the reverse transcriptase-polymerase chain reaction, with recurrence and survival in patients with colorectal cancer.<h4>Design, setting, and participants</h4>Prospective study of 257 patients with pN0 colorectal cancer enrolled between March 2002 and J2009-01-01T00:00:00Z2009 Feb2025-04-03T23:34:09.815Z2019-03-27T00:25:32ZS-EPMC27560121922475110.1001/jama.2009.141